Agilent Technologies Inc. A
i
Market dataready · fetched 2026-11-12T15:23:44.110Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T15:23:32.506968863Z
FundamentalsSEC EDGAR · ready · as of 2026-07-31 · fetched 2026-11-12T15:23:42.892853+00:00
Agilent Technologies Inc. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 181.26 | 38.4% | 5.9% | 163.48 | 42.8% | 5.8% |
| 25Δ | 179.51 | 38.8% | 5.1% | 165.63 | 40.6% | 4.7% |
| 30Δ | 177.98 | 38.1% | 4.4% | 167.20 | 38.9% | 4.0% |
| 35Δ | 176.45 | 37.3% | 3.8% | 168.77 | 37.1% | 3.3% |
| 40Δ | 174.94 | 36.5% | 3.1% | 170.23 | 35.6% | 2.7% |
| 45Δ | 173.73 | 37.0% | 2.8% | 171.32 | 34.8% | 2.3% |
| 50Δ | 172.53 | 37.5% | 2.4% | 172.41 | 34.0% | 2.0% |
| 55Δ | 171.32 | 38.0% | 2.1% | 173.50 | 33.2% | 1.6% |
| 60Δ | 170.11 | 38.5% | 1.8% | 174.58 | 32.3% | 1.3% |
| 65Δ | 168.58 | 39.7% | 1.5% | 175.77 | 31.9% | 1.0% |
| 70Δ | 167.01 | 40.9% | 1.3% | 177.01 | 31.8% | 0.8% |
| 75Δ | 165.44 | 42.2% | 1.0% | 178.26 | 31.6% | 0.6% |
| 80Δ | 163.35 | 43.4% | 0.8% | 179.50 | 31.5% | 0.4% |
20Δ
- Pseudo strike
- 181.26
- IV
- 38.4%
- B/E move
- 5.9%
- Pseudo strike
- 163.48
- IV
- 42.8%
- B/E move
- 5.8%
25Δ
- Pseudo strike
- 179.51
- IV
- 38.8%
- B/E move
- 5.1%
- Pseudo strike
- 165.63
- IV
- 40.6%
- B/E move
- 4.7%
30Δ
- Pseudo strike
- 177.98
- IV
- 38.1%
- B/E move
- 4.4%
- Pseudo strike
- 167.20
- IV
- 38.9%
- B/E move
- 4.0%
35Δ
- Pseudo strike
- 176.45
- IV
- 37.3%
- B/E move
- 3.8%
- Pseudo strike
- 168.77
- IV
- 37.1%
- B/E move
- 3.3%
40Δ
- Pseudo strike
- 174.94
- IV
- 36.5%
- B/E move
- 3.1%
- Pseudo strike
- 170.23
- IV
- 35.6%
- B/E move
- 2.7%
45Δ
- Pseudo strike
- 173.73
- IV
- 37.0%
- B/E move
- 2.8%
- Pseudo strike
- 171.32
- IV
- 34.8%
- B/E move
- 2.3%
50Δ
- Pseudo strike
- 172.53
- IV
- 37.5%
- B/E move
- 2.4%
- Pseudo strike
- 172.41
- IV
- 34.0%
- B/E move
- 2.0%
55Δ
- Pseudo strike
- 171.32
- IV
- 38.0%
- B/E move
- 2.1%
- Pseudo strike
- 173.50
- IV
- 33.2%
- B/E move
- 1.6%
60Δ
- Pseudo strike
- 170.11
- IV
- 38.5%
- B/E move
- 1.8%
- Pseudo strike
- 174.58
- IV
- 32.3%
- B/E move
- 1.3%
65Δ
- Pseudo strike
- 168.58
- IV
- 39.7%
- B/E move
- 1.5%
- Pseudo strike
- 175.77
- IV
- 31.9%
- B/E move
- 1.0%
70Δ
- Pseudo strike
- 167.01
- IV
- 40.9%
- B/E move
- 1.3%
- Pseudo strike
- 177.01
- IV
- 31.8%
- B/E move
- 0.8%
75Δ
- Pseudo strike
- 165.44
- IV
- 42.2%
- B/E move
- 1.0%
- Pseudo strike
- 178.26
- IV
- 31.6%
- B/E move
- 0.6%
80Δ
- Pseudo strike
- 163.35
- IV
- 43.4%
- B/E move
- 0.8%
- Pseudo strike
- 179.50
- IV
- 31.5%
- B/E move
- 0.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 32.86% | |
| 33.55% | |
| 33.90% | |
| 39.03% | |
| 35.60% | |
| 36.95% | |
| 36.82% | |
| 38.09% | |
| 29.38% | |
| 29.35% | |
| 29.79% | |
| 29.54% | |
| 28.48% | |
| 28.58% | |
| 29.78% | |
| 31.55% | |
| 31.15% | |
| 31.47% | |
| 29.91% | |
| 31.17% | |
| 30.94% | |
| 34.20% | |
| 34.25% | |
| 30.06% | |
| 32.41% | |
| 31.14% | |
| 31.51% | |
| 33.04% | |
| 33.04% | |
| 34.59% | |
| 33.06% | |
| 32.70% | |
| 32.61% | |
| 32.07% | |
| 33.74% | |
| 34.38% | |
| 34.48% | |
| 35.24% | |
| 35.00% | |
| 36.62% | |
| 35.69% | |
| 38.62% | |
| 34.23% | |
| 34.46% | |
| 35.35% | |
| 34.76% | |
| 36.93% | |
| 35.51% | |
| 36.32% | |
| 35.57% | |
| 35.73% | |
| 36.08% | |
| 37.57% |
Diagnostics & Research
ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is…
More →BLLN
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company is headquartered in Menlo Park, California.
More →CDNA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
More →CRL
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell…
More →CSTL
Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests, particularly within the skin cancer sector,…
More →DGX
Description unavailable
More →